The characteristics of patients with chronic hepatitis B in Turkey.

AIM To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. METHODS By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. RESULTS Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. CONCLUSION Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers.

[1]  Gretchen A. Stevens,et al.  The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions , 2012, BMC Infectious Diseases.

[2]  G. Borsboom,et al.  Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review , 2011, BMC infectious diseases.

[3]  B. Aygen,et al.  Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. , 2011, World journal of gastroenterology.

[4]  S. Hutchinson,et al.  Hepatitis B prevention, diagnosis, treatment and care: a review. , 2011, Occupational medicine.

[5]  N. Gozel,et al.  Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider , 2011, Journal of viral hepatitis.

[6]  Z. Said An overview of occult hepatitis B virus infection. , 2011, World journal of gastroenterology.

[7]  Muhammad Idrees,et al.  Hepatitis B virus in Pakistan: A systematic review of prevalence, risk factors, awareness status and genotypes , 2011, Virology Journal.

[8]  R. Merrill,et al.  Seroprevalence of markers for hepatitis B viral infection. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  Z. Abbas,et al.  Prevalence of hepatitis D in HBsAg positive patients visiting liver clinics. , 2009, JPMA. The Journal of the Pakistan Medical Association.

[10]  S. Farhang,et al.  The frequency of hepatitis D virus in patients with hepatitis B in Iran: an increasing rate? , 2009, Tropical doctor.

[11]  I. Gareen,et al.  National Institutes of Health consensus development conference statement: Management of hepatitis B , 2009, Hepatology.

[12]  M. Hussain,et al.  The increasing prevalence of hepatitis delta virus (HDV) infection in South London , 2008, Journal of medical virology.

[13]  D. Toprak,et al.  Hepatitis B and C virus in West-Central Turkey: seroprevalence in healthy individuals admitted to a university hospital for routine health checks. , 2006, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[14]  C. Saban,et al.  Trends in Hepatitis B and Hepatitis C Virus among Blood Donors over 16 Years in Turkey , 2006, European Journal of Epidemiology.

[15]  Y. Liaw The current management of HBV drug resistance. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  H. Leblebicioglu,et al.  Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. , 2005, World journal of gastroenterology.

[17]  Mei Huang,et al.  YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. , 2005, World journal of gastroenterology.

[18]  Dursun Mehmet,et al.  Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. , 2005, Japanese journal of infectious diseases.

[19]  MustafaSunbul,et al.  Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey , 2005 .

[20]  W. Hou,et al.  Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. , 2005, Journal of Zhejiang University. Science. B.

[21]  B. Donovan Sexually transmissible infections other than HIV , 2004, The Lancet.

[22]  T. Wright Clinical trial results and treatment resistance with lamivudine in hepatitis B. , 2004, Seminars in liver disease.

[23]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[24]  Yoshiyuki Suzuki,et al.  Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine , 2003, Journal of Gastroenterology.

[25]  A. Lok,et al.  World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.

[26]  B. McMahon,et al.  Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus , 2001, Annals of Internal Medicine.

[27]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[28]  E. Kırımi,et al.  Seroepidemiology of Hepatitis B Virus Infection in Children in The Eastern Anatolia , 2001 .

[29]  A. Kence,et al.  Polymorphism of Precore Region of Hepatitis B Virus DNA among Patients with Chronic HBV Infection in Turkey , 1999, Infection.

[30]  F. Mahoney,et al.  Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection , 1999, Clinical Microbiology Reviews.

[31]  E. Sagnelli,et al.  Decrease in HDV endemicity in Italy. , 1997, Journal of hepatology.

[32]  M. Kane Global programme for control of hepatitis B infection. , 1995, Vaccine.

[33]  R. Lambotte [Sexually transmissible diseases other than AIDS]. , 1994, Revue medicale de Liege.